Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Characteristics of 9MW3011 in Healthy Volunteers

Next Previous
Trial Profile

A Single-center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Characteristics of 9MW3011 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 9MW 3011 (Primary)
  • Indications Beta-thalassaemia; Iron overload; Polycythaemia vera
  • Focus Adverse reactions; First in man
  • Sponsors Mabwell (Shanghai) Bioscience

Most Recent Events

  • 14 May 2025 According to a Disc Medicine Media Release, company will present data from this trial at the upcoming European Hematology Association (EHA) 2025 Congress, which will be held in Milan, Italy on June 12-15, 2025.The management will host a call to review the presented data on June 16 at 8:00 am ET.
  • 27 Dec 2024 Status changed from active, no longer recruiting to completed.
  • 05 Nov 2024 According to a Disc Medicine Media Release, company will present data from this trial at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, CA on Dec 7-10, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top